Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
Open accessThe DOI matches its Crossref record; 41 of the 42 references it cites were found in a registry or an index.
Abstract
BACKGROUND: All-trans retinoic acid (ATRA) with chemotherapy is the standard of care for acute promyelocytic leukemia (APL), resulting in cure rates exceeding 80%. Pilot studies of treatment with arsenic trioxide with or without ATRA have shown high efficacy and reduced hematologic toxicity. METHODS: We conducted a phase 3, multicenter trial comparing ATRA plus chemotherapy with ATRA plus arsenic trioxide in patients with APL classified as low-to-intermediate risk (white-cell count, ≤10×10(9) per liter). Patients were randomly assigned to receive either ATRA plus arsenic trioxide for induction and consolidation therapy or standard ATRA-idarubicin induction therapy followed by three cycles of consolidation therapy with ATRA plus chemotherapy and maintenance therapy with low-dose chemotherapy and ATRA. The study was designed as a noninferiority trial to show that the difference between the rates of event-free survival at 2 years in the two groups was not greater than 5%. RESULTS: Complete remission was achieved in all 77 patients in the ATRA-arsenic trioxide group who could be evaluated (100%) and in 75 of 79 patients in the ATRA-chemotherapy group (95%) (P=0.12). The median follow-up was 34.4 months. Two-year event-free survival rates were 97% in the ATRA-arsenic trioxide group and 86% in the ATRA-chemotherapy group (95% confidence interval for the difference, 2 to 22 percentage points; P<0.001 for noninferiority and P=0.02 for superiority of ATRA-arsenic trioxide). Overall survival was also better with ATRA-arsenic trioxide (P=0.02). As compared with ATRA-chemotherapy, ATRA-arsenic trioxide was associated with less hematologic toxicity and fewer infections but with more hepatic toxicity. CONCLUSIONS: ATRA plus arsenic trioxide is at least not inferior and may be superior to ATRA plus chemotherapy in the treatment of patients with low-to-intermediate-risk APL. (Funded by Associazione Italiana contro le Leucemie and others; ClinicalTrials.gov number, NCT00482833.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Citations
Cites
Bennett, J. M., Catovsky, D., Daniel, M., Flandrin, G., Galton, D. A. G., Gralnick, H. R., & Sultan, C. (1976) · British Journal of Haematology · doi:10.1111/j.1365-2141.1976.tb03563.x · Cited by 5,602
Cheson, B. D., Bennett, J. M., Kopecky, K. J., Büchner, T., Willman, C. L., Estey, E. H., Schiffer, C. A., Doehner, H., Tallman, M. S., Lister, T. A., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.036 · Cited by 2,654
Self-citationCreutzig, U., & Kaspers, G. J. L. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.99.116 · Cited by 2,137
Thiede, C., Steudel, C., Mohr, B., Schaich, M., Schäkel, U., Platzbecker, U., Wermke, M., Bornhäuser, M., Ritter, M., Neubauer, A., et al. (2002) · Blood · doi:10.1182/blood.v99.12.4326 · Cited by 1,735
Self-citationShen, Z.-X., Chen, G.-Q., Ni, J.-H., Li, X.-S., Xiong, S.-M., Qiu, Q.-Y., Zhu, J., Tang, W., Sun, G.-L., Yang, K.-Q., et al. (1997) · Blood · doi:10.1182/blood.v89.9.3354 · Cited by 1,428
Gabert, J., Beillard, E., van der Velden, V. H. J., Bi, W., Grimwade, D., Pallisgaard, N., Barbany, G., Cazzaniga, G., Cayuela, J. M., Cavé, H., et al. (2003) · Leukemia · doi:10.1038/sj.leu.2403135 · Cited by 1,284
Acute promyelocytic leukemia: from highly fatal to highly curable
Wang, Z.-Y., & Chen, Z. (2008) · Blood · doi:10.1182/blood-2007-07-102798 · Cited by 1,277
van Dongen, J., Macintyre, E., Gabert, J., Delabesse, E., Rossi, V, Saglio, G., Gottardi, E., Rambaldi, A., Dotti, G., Griesinger, F., et al. (1999) · Leukemia · doi:10.1038/sj.leu.2401592 · Cited by 1,169
Self-citationSanz, M. A., Grimwade, D., Tallman, M. S., Lowenberg, B., Fenaux, P., Estey, E. H., Naoe, T., Lengfelder, E., Büchner, T., Döhner, H., et al. (2009) · Blood · doi:10.1182/blood-2008-04-150250 · Cited by 947
Self-citationUnited States Multicenter Study of Arsenic Trioxide in Relapsed Acute Promyelocytic Leukemia
Soignet, S. L., Frankel, S. R., Douer, D., Tallman, M. S., Kantarjian, H., Calleja, E., Stone, R. M., Kalaycio, M., Scheinberg, D. A., Steinherz, P., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.18.3852 · Cited by 826 · cited 1×
“A genetic diagnosis could be established by detection of the PML-RARA fusion gene by means of reverse-transcriptase–polymerase-chain-reaction (RT-PCR) assay,28,29 demonstration of the t(15;17) translocation by means of conventional karyotyping or fluorescence in situ hybridization (FISH),30 or evidence of a microspeck…”
Research works printed but not linked: 3
- Zhang P, 1996, Chin J Hematol, 17, 58
- Sanz MA, 2000, Blood, 96, 1247
- Grimwade D, 2000, Blood, 96, 1297
Cited by
Cancer metabolism: a therapeutic perspective
Martinez-Outschoorn, U. E., Peiris-Pagés, M., Pestell, R. G., Sotgia, F., & Lisanti, M. P. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.60 · Cited by 1,505
FTO Plays an Oncogenic Role in Acute Myeloid Leukemia as a N 6 -Methyladenosine RNA Demethylase
Li, Z., Weng, H., Su, R., Weng, X., Zuo, Z., Li, C., Huang, H., Nachtergaele, S., Dong, L., Hu, C., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2016.11.017 · Cited by 1,508
Transcriptional Addiction in Cancer
Bradner, J. E., Hnisz, D., & Young, R. A. (2017) · Cell · doi:10.1016/j.cell.2016.12.013 · Cited by 1,194
“Notably, innovation in clinical investigation would 9 ultimately pair ATRA with arsenic trioxide (also associated with PML-RARA degradation) in low- to intermediate-risk APML as effective first-line treatment, equivalent in efficacy to chemotherapy in this disease (Lo-Coco et al., 2013).”
Pancreatic cancer stroma: an update on therapeutic targeting strategies
Hosein, A. N., Brekken, R. A., & Maitra, A. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-0300-1 · Cited by 950
Acute myeloid leukemia: current progress and future directions
Kantarjian, H., Kadia, T., DiNardo, C., Daver, N., Borthakur, G., Jabbour, E., Garcia-Manero, G., Konopleva, M., & Ravandi, F. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00425-3 · Cited by 776
“(9) Approaches to enhance T-cell immune responses to AML (as done in ALL) with T-cell engagers (BiTEs), checkpoint inhibitors, and chimeric antigen receptor (CAR)-T-cell approaches.”
BackgroundSanz, M. A., Fenaux, P., Tallman, M. S., Estey, E. H., Löwenberg, B., Naoe, T., Lengfelder, E., Döhner, H., Burnett, A. K., Chen, S.-J., et al. (2019) · Blood · doi:10.1182/blood-2019-01-894980 · Cited by 664
Self-citationKhwaja, A., Bjorkholm, M., Gale, R. E., Levine, R. L., Jordan, C. T., Ehninger, G., Bloomfield, C. D., Estey, E., Burnett, A., Cornelissen, J. J., et al. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.10 · Cited by 592
Self-citationAn update of current treatments for adult acute myeloid leukemia
Dombret, H., & Gardin, C. (2016) · Blood · doi:10.1182/blood-2015-08-604520 · Cited by 550
Burnett, A. K., Russell, N. H., Hills, R. K., Bowen, D., Kell, J., Knapper, S., Morgan, Y. G., Lok, J., Grech, A., Jones, G., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00193-x · Cited by 534
The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia
Issa, G. C., Aldoss, I., DiPersio, J., Cuglievan, B., Stone, R., Arellano, M., Thirman, M. J., Patel, M. R., Dickens, D. S., Shenoy, S., et al. (2023) · Nature · doi:10.1038/s41586-023-05812-3 · Cited by 507
IDH mutations in cancer and progress toward development of targeted therapeutics
Dang, L., Yen, K., & Attar, E. C. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw013 · Cited by 509
“The noncytotoxic differentiation regime of ATRA + arsenic trioxide (ATO) has been shown to be similar to ATRA + chemotherapy in achieving CR and superior in OS [102].”
ResultSykes, D. B., Kfoury, Y. S., Mercier, F. E., Wawer, M. J., Law, J. M., Haynes, M. K., Lewis, T. A., Schajnovitz, A., Jain, E., Lee, D., et al. (2016) · Cell · doi:10.1016/j.cell.2016.08.057 · Cited by 500
“…24 36 48 72 96 120 GMP CMP GRAN HSCday 0 day 2 day 3 day 4 day 5 day 6 day 7 day 1 0 4 8 12 24 36 48 72 96 120 F GMurine Human [hrs] [hrs] (legend on next page) 172 Cell 167, 171–186, September 22, 2016 the best outlook for cure, with overall survival rates in excess of 85% (Lo-Coco et al., 2013).”
Acute myeloid leukemia: 2023 update on diagnosis, risk‐stratification, and management
Shimony, S., Stahl, M., & Stone, R. M. (2023) · American Journal of Hematology · doi:10.1002/ajh.26822 · Cited by 448
Hoelzer, D., Bassan, R., Dombret, H., Fielding, A., Ribera, J. M., & Buske, C. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw025 · Cited by 463
DiNardo, C. D., Erba, H. P., Freeman, S. D., & Wei, A. H. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00108-3 · Cited by 437
Differentiation therapy revisited
de Thé, H. (2018) · Nature reviews. Cancer · doi:10.1038/nrc.2017.103 · Cited by 462
Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance
Grimwade, D., Ivey, A., & Huntly, B. J. P. (2016) · Blood · doi:10.1182/blood-2015-07-604496 · Cited by 445
McMahon, C. M., Ferng, T., Canaani, J., Wang, E. S., Morrissette, J. J. D., Eastburn, D. J., Pellegrino, M., Durruthy-Durruthy, R., Watt, C. D., Asthana, S., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1453 · Cited by 446
“Our hope is that such studies will one day lead to rational, targeted, and dynamic combinatorial approaches that prolong response or facilitate cure in AML without transplantation or reliance on a traditional cytotoxic backbone, as is now true for acute promyelocytic leukemia (32).”
BackgroundRetinoic acid receptors: From molecular mechanisms to cancer therapy
di Masi, A., Leboffe, L., De Marinis, E., Pagano, F., Cicconi, L., Rochette-Egly, C., Lo-Coco, F., Ascenzi, P., & Nervi, C. (2015) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2014.12.003 · Cited by 403
Self-citationPlatzbecker, U., Avvisati, G., Cicconi, L., Thiede, C., Paoloni, F., Vignetti, M., Ferrara, F., Divona, M., Albano, F., Efficace, F., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.1982 · Cited by 389
“By contrast, new relapses, two instances of molecular resistance (ie, testing PCR positive after third consolidation), and two therapy-related myeloid neoplasms were observed in the group of patients receiving ATRA-CHT.”
BackgroundResultInfluentialSelf-citationCollaborative Efforts Driving Progress in Pediatric Acute Myeloid Leukemia
Zwaan, C. M., Kolb, E. A., Reinhardt, D., Abrahamsson, J., Adachi, S., Aplenc, R., De Bont, E. S. J. M., De Moerloose, B., Dworzak, M., Gibson, B. E. S., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.8289 · Cited by 383
“02 for superiority).(99) COG investigators recently reported at scientific meetings the favorable safety and tolerability of ATO in combination with conventional chemotherapy, but data are still unpublished.”
BackgroundAdvances in the Treatment of Acute Myeloid Leukemia: New Drugs and New Challenges
Short, N. J., Konopleva, M., Kadia, T. M., Borthakur, G., Ravandi, F., DiNardo, C. D., & Daver, N. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1011 · Cited by 368
“, inv(16)/t(16;16), t(8;21), t(15;17), inv(3)/t(3:3), t(6;9), and KMT2A translocations], 3 new heterogeneous subtypes of AML were defined, including AML with mutations of genes regulating RNA splicing (e.”
BackgroundThe PI3K-Akt-mTOR Signaling Pathway in Human Acute Myeloid Leukemia (AML) Cells
Nepstad, I., Hatfield, K. J., Grønningsæter, I. S., & Reikvam, H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21082907 · Cited by 348
Acute Myeloid Leukemia: A Concise Review
Saultz, J., & Garzon, R. (2016) · Journal of Clinical Medicine · doi:10.3390/jcm5030033 · Cited by 342
“%) in the ATO-ATRA arm than for those in the ATRA–chemotherapy arm (86% and 91”
BackgroundInfluentialWhat has traditional Chinese medicine delivered for modern medicine?
Wang, J., Wong, Y.-K., & Liao, F. (2018) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2018.3 · Cited by 328
Pollyea, D. A., Bixby, D., Perl, A., Bhatt, V. R., Altman, J. K., Appelbaum, F. R., de Lima, M., Fathi, A. T., Foran, J. M., Gojo, I., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0002 · Cited by 320
Acute Promyelocytic Leukemia: A Paradigm for Oncoprotein-Targeted Cure
de Thé, H., Pandolfi, P. P., & Chen, Z. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.10.002 · Cited by 297
“…aim at covering the most recent developments that led to the current gold standard: the RA/arsenic combination, which allows chemotherapy-free APL eradication, at least in standard-risk patients (Burnett et al., 2015; Lo-Coco et al., 2013; Platzbecker et al., 2017; Ravandi and Kantarjian, 2015).”
BackgroundAbaza, Y., Kantarjian, H., Garcia-Manero, G., Estey, E., Borthakur, G., Jabbour, E., Faderl, S., O’Brien, S., Wierda, W., Pierce, S., et al. (2017) · Blood · doi:10.1182/blood-2016-09-736686 · Cited by 286
Heuser, M., Ofran, Y., Boissel, N., Brunet Mauri, S., Craddock, C., Janssen, J., Wierzbowska, A., & Buske, C. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.02.018 · Cited by 284
Lehmann, B. D., Colaprico, A., Silva, T. C., Chen, J., An, H., Ban, Y., Huang, H., Wang, L., James, J. L., Balko, J. M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26502-6 · Cited by 279
Acute promyelocytic leukemia: where did we start, where are we now, and the future
Coombs, C. C., Tavakkoli, M., & Tallman, M. S. (2015) · Blood Cancer Journal · doi:10.1038/bcj.2015.25 · Cited by 280
Targeting Transcription Factors in Cancer
Bhagwat, A. S., & Vakoc, C. R. (2015) · Trends in Cancer · doi:10.1016/j.trecan.2015.07.001 · Cited by 276
Wei, S., Kozono, S., Kats, L., Nechama, M., Li, W., Guarnerio, J., Luo, M., You, M.-H., Yao, Y., Kondo, A., et al. (2015) · Nature Medicine · doi:10.1038/nm.3839 · Cited by 272
Self-citationMutations in AML: prognostic and therapeutic implications
DiNardo, C. D., & Cortes, J. E. (2016) · Hematology · doi:10.1182/asheducation-2016.1.348 · Cited by 268
Grimwade, D., & Freeman, S. D. (2014) · Blood · doi:10.1182/blood-2014-05-577593 · Cited by 262
Acute Myeloid Leukemia: 2025 Update on Diagnosis, Risk‐Stratification, and Management
Shimony, S., Stahl, M., & Stone, R. M. (2025) · American Journal of Hematology · doi:10.1002/ajh.27625 · Cited by 223
“This entity has an excellent prognosis, especially in comparison to other non-APL AML subtypes [27–33].”
Acute promyelocytic leukemia current treatment algorithms
Yilmaz, M., Kantarjian, H., & Ravandi, F. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00514-3 · Cited by 238
Targeting multiple signaling pathways: the new approach to acute myeloid leukemia therapy
Carter, J. L., Hege, K., Yang, J., Kalpage, H. A., Su, Y., Edwards, H., Hüttemann, M., Taub, J. W., & Ge, Y. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00361-x · Cited by 218
Ablain, J., Rice, K., Soilihi, H., de Reynies, A., Minucci, S., & de Thé, H. (2014) · Nature Medicine · doi:10.1038/nm.3441 · Cited by 191
How we prevent and treat differentiation syndrome in patients with acute promyelocytic leukemia
Sanz, M. A., & Montesinos, P. (2014) · Blood · doi:10.1182/blood-2013-10-512640 · Cited by 182
Acute Myeloid Leukemia, Version 2.2013
O’Donnell, M. R., Tallman, M. S., Abboud, C. N., Altman, J. K., Appelbaum, F. R., Arber, D. A., Attar, E., Borate, U., Coutre, S. E., Damon, L. E., et al. (2013) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2013.0127 · Cited by 175
Targeting Aberrant Epigenetic Networks Mediated by PRMT1 and KDM4C in Acute Myeloid Leukemia
Cheung, N., Fung, T. K., Zeisig, B. B., Holmes, K., Rane, J. K., Mowen, K. A., Finn, M. G., Lenhard, B., Chan, L. C., & So, C. W. E. (2016) · Cancer Cell · doi:10.1016/j.ccell.2015.12.007 · Cited by 175
“Understanding themechanisms of action is essential, and has been instrumental in designing more effective therapeutic strategies to minimize and overcome relapses (Cortes et al., 2012; Lo-Coco et al., 2013).”
BackgroundAcute myeloid leukemia—Major progress over four decades and glimpses into the future
Kantarjian, H. (2016) · American Journal of Hematology · doi:10.1002/ajh.24246 · Cited by 174
Moujalled, D. M., Pomilio, G., Ghiurau, C., Ivey, A., Salmon, J., Rijal, S., Macraild, S., Zhang, L., Teh, T.-C., Tiong, I.-S., et al. (2019) · Leukemia · doi:10.1038/s41375-018-0261-3 · Cited by 174
Updates on targeted therapies for acute myeloid leukaemia
Kayser, S., & Levis, M. J. (2022) · British Journal of Haematology · doi:10.1111/bjh.17746 · Cited by 162
“Published data from a large multicentre phase III randomized trial on the direct comparison of ATO/ATRA versus ATRA in combination with idarubicin (AIDA) or mitoxantrone in adult patients with de novo, non-high-risk APL showed remarkably favourable results for ATO/ATRA, with a two-year event-free survival (EFS) rate o…”
ResultClonal evolution in hematological malignancies and therapeutic implications
Landau, D. A., Carter, S. L., Getz, G., & Wu, C. J. (2014) · Leukemia · doi:10.1038/leu.2013.248 · Cited by 164
Iland, H. J., Collins, M., Bradstock, K., Supple, S. G., Catalano, A., Hertzberg, M., Browett, P., Grigg, A., Firkin, F., Campbell, L. J., et al. (2015) · The Lancet Haematology · doi:10.1016/s2352-3026(15)00115-5 · Cited by 167
Hore, T. A., von Meyenn, F., Ravichandran, M., Bachman, M., Ficz, G., Oxley, D., Santos, F., Balasubramanian, S., Jurkowski, T. P., & Reik, W. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1608679113 · Cited by 165
Secondary mutations as mediators of resistance to targeted therapy in leukemia
Daver, N. G., Cortes, J. E., Ravandi, F., Patel, K. P., Burger, J. A., Konopleva, M. Y., & Kantarjian, H. M. (2015) · Blood · doi:10.1182/blood-2014-10-605808 · Cited by 170
Unlocking the potential of retinoic acid in anticancer therapy
Schenk, T., Stengel, S., & Zelent, A. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.412 · Cited by 160
Kumar, S., Yedjou, C. G., & Tchounwou, P. B. (2014) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-33-42 · Cited by 159
“It is used alone or combination with all trans retinoic acid (ATRA) to achieve complete remission and maximum survival rate [8,9].”
BackgroundMartelli, M. P., Gionfriddo, I., Mezzasoma, F., Milano, F., Pierangeli, S., Mulas, F., Pacini, R., Tabarrini, A., Pettirossi, V., Rossi, R., et al. (2015) · Blood · doi:10.1182/blood-2014-11-611459 · Cited by 139
“retinoic acid receptor α (RARα) gene rearrangement.(2)”
Doubly blind: a systematic review of gender in randomised controlled trials
Phillips, S. P., & Hamberg, K. (2016) · Global Health Action · doi:10.3402/gha.v9.29597 · Cited by 155
“Lo-Coco (primarily public, drugs donated by industry) (49) Comparison of two drug regimens to treat promyelocytic leukaemia New drug treatment was no better than old treatment N 156 Women 51% Reported as non-inferior”
BackgroundRetinoids and rexinoids in cancer prevention: from laboratory to clinic
Uray, I. P., Dmitrovsky, E., & Brown, P. H. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.09.002 · Cited by 161
“86%) and overall survival rates with the combination of atRA with arsenic trioxide than with chemotherapy [62].”
BackgroundDifferentiation syndrome in acute promyelocytic leukaemia
Stahl, M. F., & Tallman, M. S. (2019) · British Journal of Haematology · doi:10.1111/bjh.16151 · Cited by 152
“If patients were receiving prophylactic prednisone, we switch to dexamethasone for treatment of APL DS, as described by Lo-Coco et al (2013).”
BackgroundMethodInfluentialLiquori, A., Ibáñez, M., Sargas, C., Sanz, M. Á., Barragán, E., & Cervera, J. (2020) · Cancers · doi:10.3390/cancers12030624 · Cited by 159
“, Midostaurin for FLT3mut, and Enasidenib for IDHmut), APL has been a pioneer, considering that this has been a reality for this neoplasm for 30 years [8,172].”
BackgroundVitamin A, Cancer Treatment and Prevention: The New Role of Cellular Retinol Binding Proteins
Doldo, E., Costanza, G., Agostinelli, S., Tarquini, C., Ferlosio, A., Arcuri, G., Passeri, D., Scioli, M. G., & Orlandi, A. (2015) · BioMed Research International · doi:10.1155/2015/624627 · Cited by 147
“Effectiveness of ATRA in the treatment of APL observed in more than 90% of the patients leading to the complete remission [53–55].”
BackgroundFrontline treatment of acute myeloid leukemia in adults
Tamamyan, G., Kadia, T. M., Ravandi, F., Borthakur, G. M., Cortes, J. E., Jabbour, E. J., Daver, N. G., Ohanian, M. N., Kantarjian, H. M., & Konopleva, M. Y. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.12.004 · Cited by 179
Drug Combination in Cancer Treatment—From Cocktails to Conjugated Combinations
Gilad, Y., Gellerman, G., Lonard, D. M., & O’Malley, B. W. (2021) · Cancers · doi:10.3390/cancers13040669 · Cited by 166
Current management of newly diagnosed acute promyelocytic leukemia
Cicconi, L., & Lo‐Coco, F. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw171 · Cited by 145
“This complication may occur in up to 60% of cases [20]; however, it is generally reversible and successfully managed with a decrement or temporary discontinuation of ATO and/or ATRA.”
BackgroundMethodResultInfluentialSelf-citationZhu, H., Wu, D., Du, X., Zhang, X., Liu, L., Ma, J., Shao, Z., Ren, H., Hu, J., Xu, K., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30295-x · Cited by 154
Nguyen, P. H., Giraud, J., Staedel, C., Chambonnier, L., Dubus, P. R., Chevret, E., Bœuf, H., Gauthereau, X., Rousseau, B., Fevre, M., et al. (2016) · Oncogene · doi:10.1038/onc.2016.87 · Cited by 144
dos Santos, G. A., Kats, L., & Pandolfi, P. P. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20131121 · Cited by 145
Resistance to Therapy in Acute Promyelocytic Leukemia
Lehmann‐Che, J., Bally, C., & de Thé, H. (2014) · New England Journal of Medicine · doi:10.1056/nejmc1409040 · Cited by 140
Morandi, A., Taddei, M. L., Chiarugi, P., & Giannoni, E. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00040 · Cited by 157
“Crucially, arsenic trioxide has been proposed for the clinical management of relapsed or refractory acute promyelocytic leukemia (183), while metformin particularly exerts anticancer activity in patients with breast, endometrial, or prostate cancer (184, 185).”
BackgroundCurrent status and research directions in acute myeloid leukemia
Kantarjian, H. M., Borthakur, G. M., Daver, N. G., Dinardo, C. D., Issa, G. C., Jabbour, E. J., Kadia, T. M., Sasaki, K., Short, N. J., Yilmaz, M. E., et al. (2024) · Blood Cancer Journal · doi:10.1038/s41408-024-01143-2 · Cited by 158
Lu, Z., Xie, J., Wu, G., Shen, J., Collins, R., Chen, W., Kang, X., Luo, M., Zou, Y., Huang, L. J.-S., et al. (2017) · Nature Medicine · doi:10.1038/nm.4252 · Cited by 139
Creed, S. J., & McKenzie, M. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9027-6_5 · Cited by 161
Retinoids and breast cancer: From basic studies to the clinic and back again
Garattini, E., Bolis, M., Garattini, S. K., Fratelli, M., Centritto, F., Paroni, G., Gianni’, M., Zanetti, A., Pagani, A., Fisher, J. N., et al. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.01.001 · Cited by 141
“mary tumors probably via down-regulation of PPARb/d activity [14].”
BackgroundInfluentialComprehensive mutational analysis of primary and relapse acute promyelocytic leukemia
Madan, V., Shyamsunder, P., Han, L., Mayakonda, A., Nagata, Y., Sundaresan, J., Kanojia, D., Yoshida, K., Ganesan, S., Hattori, N., et al. (2016) · Leukemia · doi:10.1038/leu.2016.69 · Cited by 143
“21,22 Both ATRA and ATO target PML-RARA fusion protein and trigger its degradation by non-overlapping mechanisms, leading to restoration of normal retinoid signaling.”
Self-citationFructose 2,6-Bisphosphate in Cancer Cell Metabolism
Bartrons, R., Simon‐Molas, H., Rodríguez‐García, A., Castaño, E., Navarro‐Sabaté, À., Manzano, À., & Martinez‐Outschoorn, U. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00331 · Cited by 148
Ehrhardt, M. J., Krull, K. R., Bhakta, N. H., Liu, Q., Yasui, Y., Robison, L. L., & Hudson, M. M. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00802-w · Cited by 157
The simpler, the better: oral arsenic for acute promyelocytic leukemia
Zhu, H., Hu, J., Lo‐Coco, F., & Jin, J. (2019) · Blood · doi:10.1182/blood.2019000760 · Cited by 133
Self-citationResistance to Arsenic Therapy in Acute Promyelocytic Leukemia
Zhu, H.-H., Qin, Y.-Z., & Huang, X.-J. (2014) · New England Journal of Medicine · doi:10.1056/nejmc1316382 · Cited by 128
Acute promyelocytic leukemia (APL): a review of the literature
Jimenez, J. J., Chale, R. S., Abad, A. C., & Schally, A. V. (2020) · Oncotarget · doi:10.18632/oncotarget.27513 · Cited by 137
Translational implications of somatic genomics in acute myeloid leukaemia
Meyer, S. C., & Levine, R. L. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70008-7 · Cited by 149
Outlook on PI3K/AKT/mTOR inhibition in acute leukemia
Fransecky, L. R., Mochmann, L. H., & Baldus, C. D. (2015) · Molecular and Cellular Therapies · doi:10.1186/s40591-015-0040-8 · Cited by 135
“Moreover, in AML, the translocation t(15;17)(q22;q12) produces a fusion protein called PML-RARA [12], which is pathognomonic for acute promyelocytic leukemia (APL).”
BackgroundMolecular therapy for acute myeloid leukaemia
Coombs, C. C., Tallman, M. S., & Levine, R. L. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.210 · Cited by 132
Maintenance therapy in AML: The past, the present and the future
Molica, M., Breccia, M., Foà, R., Jabbour, E. J., & Kadia, T. M. (2019) · American Journal of Hematology · doi:10.1002/ajh.25620 · Cited by 130
Self-citationLiang, C., Qiao, G., Liu, Y., Tian, L., Hui, N., Li, J., Ma, Y., Han, L., Zhao, Q., Cao, W., et al. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113451 · Cited by 125
Hajj, H. E., Dassouki, Z., Berthier, C., Raffoux, E., Adès, L., Legrand, O., Hleihel, R., Şahin, U., Tawil, N., Salameh, A., et al. (2015) · Blood · doi:10.1182/blood-2014-11-612416 · Cited by 130
Fey, M. F., & Buske, C. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt320 · Cited by 119
“If the results of ASO-ATRA induction (without chemotherapy) hold true over time, this regime might well become a new future standard, at least in low- to intermediate-risk APL [II, C] [40].”
BackgroundMetabolism in acute myeloid leukemia: mechanistic insights and therapeutic targets
Mishra, S. K., Millman, S. E., & Zhang, L. (2022) · Blood · doi:10.1182/blood.2022018092 · Cited by 141
Coordinate β-adrenergic inhibition of mitochondrial activity and angiogenesis arrest tumor growth
Nuevo‐Tapioles, C., Santacatterina, F., Stamatakis, K., de Arenas, C. N., de Cedrón, M. G., Formentini, L., & Cuezva, J. M. (2020) · Nature Communications · doi:10.1038/s41467-020-17384-1 · Cited by 126
Noguera, N. I., Catalano, G., Banella, C., Divona, M., Faraoni, I., Ottone, T., Arcese, W. G., & Voso, M. T. (2019) · Cancers · doi:10.3390/cancers11101591 · Cited by 131
“The resistance is overcome by ATO [53], reflecting the efficacy of the ATRA/ATO combination in patients with FLT3 mutation proven in different clinical studies [68,69].”
BackgroundSelf-citationAdvani, A. S., Moseley, A. B., O'Dwyer, K. M., Wood, B. L., Fang, M., Wieduwilt, M. J., Aldoss, I., Park, J. H., Klisovic, R. B., Baer, M. R., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.01766 · Cited by 116
Norsworthy, K. J., Mulkey, F. A., Scott, E., Ward, A. F., Przepiorka, D., Charlab, R., Dorff, S. E., Deisseroth, A., Kazandjian, D. G., Sridhara, R., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0834 · Cited by 120
Bravo, G. M., Kanagal‐Shamanna, R., Sasaki, K., Patel, K. P., Gañán‐Gómez, I., Jabbour, E. J., Kadia, T. M., Ravandi, F., Dinardo, C. D., Borthakur, G., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2018026989 · Cited by 118
Mantha, S. H., Goldman, D. A., Devlin, S. M., Lee, J., Zannino, D., Collins, M. L., Douer, D., Iland, H. J., Litzow, M. R., Stein, E. M., et al. (2017) · Blood · doi:10.1182/blood-2016-10-747170 · Cited by 116
TRIM8 modulates the EWS/FLI oncoprotein to promote survival in Ewing sarcoma
Seong, B. K. A., Dharia, N. V., Lin, S., Donovan, K. A., Chong, S., Robichaud, A., Conway, A., Hamze, A., Ross, L., Alexe, G., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.07.003 · Cited by 113
“Successful targeting, however, can lead to cures as exemplified by arsenic and retinoic acid treatment for patients with acute promyelocytic leukemia, both of which lead to degradation of the driver fusion-TF PML/RARa (Lo-Coco et al., 2013; Zhu et al., 2001).”
BackgroundLi, K., Wang, F., Cao, W., Lv, X., Hua, F., Cui, B., Yu, J., Zhang, X., Shang, S., Liu, S., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.04.006 · Cited by 117
Kurtz, S. E., Eide, C. A., Kaempf, A., Khanna, V., Savage, S. L., Rofelty, A., English, I., Ho, H., Pandya, R., Bolosky, W. J., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1703094114 · Cited by 110
E1 Enzymes as Therapeutic Targets in Cancer
Barghout, S. H., & Schimmer, A. D. (2020) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000053 · Cited by 118
Targeting Calcium Signaling Induces Epigenetic Reactivation of Tumor Suppressor Genes in Cancer
Raynal, N. J. ‐., Lee, J. T., Wang, Y., Beaudry, A., Madireddi, P., Garriga, J., Malouf, G. G., Dumont, S., Dettman, E. J., Gharibyan, V., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-14-2391 · Cited by 110
“Another drug we identified as having effects on gene silencing is arsenic trioxide, which has marked activity in acute promyelocytic leukemia (36), a disease characterized by a block in cell differentiation (37).”
Kutny, M. A., Alonzo, T. A., Abla, O., Rajpurkar, M., Gerbing, R. B., Wang, Y.-C., Hirsch, B. A., Raimondi, S. C., Kahwash, S. B., Hardy, K. K., et al. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2021.5206 · Cited by 115
Oral Arsenic and Retinoic Acid for Non–High-Risk Acute Promyelocytic Leukemia
Zhu, H., & Huang, X. (2014) · New England Journal of Medicine · doi:10.1056/nejmc1412035 · Cited by 102
Lübbert, M., Grishina, O., Schmoor, C., Schlenk, R. F., Jost, E., Crysandt, M. M., Heuser, M., Thol, F. R., Salih, H. R., Schittenhelm, M. M., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.01053 · Cited by 111
Self-citationAcute promyelocytic leukemia (APL): remaining challenges towards a cure for all
Stahl, M. F., & Tallman, M. S. (2019) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2019.1613540 · Cited by 106
“The MD Anderson group attempted to reduce exposure to traditional chemotherapy by adding gemtuzumab ozogamicin (GO), an anti-CD33 monoclonal antibody conjugated to the anthracycline antibiotic calicheamicin, at a dose of 9mg/m2 on day 1 of induction therapy with ATRA and ATO for high-risk APL patients, which led to 5-…”
BackgroundMethodResultInfluentialFalanga, A., Russo, L., & Milesi, V. (2014) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000072 · Cited by 100
When the good go bad: Mutant NPM1 in acute myeloid leukemia
Kunchala, P., Kuravi, S., Jensen, R. A., McGuirk, J. P., & Balusu, R. (2017) · Blood Reviews · doi:10.1016/j.blre.2017.11.001 · Cited by 104
Metadata
- Authors
- Lo-Coco, F., Avvisati, G., Vignetti, M., Thiede, C., Orlando, S. M., Iacobelli, S., Ferrara, F., Fazi, P., Cicconi, L., Di Bona, E., Specchia, G., Sica, S., Divona, M., Levis, A., Fiedler, W., Cerqui, E., Breccia, M., Fioritoni, G., Salih, H. R., Cazzola, M., Melillo, L., Carella, A. M., Brandts, C. H., Morra, E., von Lilienfeld-Toal, M., Hertenstein, B., Wattad, M., Lübbert, M., Hänel, M., Schmitz, N., Link, H., Kropp, M. G., Rambaldi, A., La Nasa, G., Luppi, M., Ciceri, F., Finizio, O., Venditti, A., Fabbiano, F., Döhner, K., Sauer, M., Ganser, A., Amadori, S., Mandelli, F., Döhner, H., Ehninger, G., Schlenk, R. F., & Platzbecker, U.
- ORCID
- Avvisati, Giuseppe
- Vignetti, Marco
- Thiede, Christian
- Iacobelli, Simona
- Ferrara, Felicetto
- Fazi, Paola
- Cicconi, Laura
- Specchia, Giorgina
- Sica, Simona
- Fiedler, Walter
- Breccia, Massimo
- Salih, Helmut R.
- Cazzola, Mario
- Melillo, Lorella
- Carella, Angelo M.
- Brandts, Christian H.
- Hertenstein, Bernd
- Lübbert, Michael
- Hänel, Matthias
- Schmitz, Norbert
- Link, Hartmut
- Rambaldi, Alessandro
- Luppi, Mario
- Ciceri, Fabio
- Finizio, Olimpia
- Venditti, Adriano
- Döhner, Konstanze
- Ganser, Arnold
- Amadori, Sergio
- Döhner, Hartmut
- Ehninger, Gerhard
- Schlenk, Richard F.
- Platzbecker, Uwe
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-07-11
- Volume
- 369
- Issue
- 2
- Pages
- 111-121
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2129338773
- Cited by
- 1,611
- References
- 42
- Citations by year
- 2026: 83 · 2025: 89 · 2024: 132 · 2023: 144 · 2022: 110 · 2021: 147 · 2020: 137 · 2019: 125 · 2018: 122 · 2017: 107 · 2016: 117 · 2015: 144 · 2014: 119 · 2013: 33
- FWCI
- 61.62
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- cc-by
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion)
- UNICA IRIS Institutional Research Information System (University of Cagliari) (submittedVersion)
- IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Health Sciences › Medicine › Hematology › Acute Lymphoblastic Leukemia research
- Keywords
- acute promyelocytic leukemia, all-trans retinoic acid, arsenic trioxide, idarubicin, induction therapy, consolidation therapy, maintenance therapy, event-free survival, overall survival, complete remission, hematologic toxicity, hepatotoxicity
- MeSH terms
- Arsenic Trioxide, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Arsenicals, Female, Humans, Male, Middle Aged, Neutropenia, Oxides, Thrombocytopenia, Tretinoin, Leukemia, Promyelocytic, Acute, Disease-Free Survival, Young Adult, Maintenance Chemotherapy, Induction Chemotherapy, Consolidation Chemotherapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.